The DOI matches its Crossref record; 128 of the 132 references it cites were found in a registry or an index, and 4 are not checked yet.
Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
Abstract
Vancomycin is a glycopeptide antibiotic that has been in clinical use for nearly 50 years as a penicillin alternative to treat penicillinase-producing strains of Staphylococcus aureus. It is one of the most widely used antibiotics in the United States for the treatment of serious gram-positive infections involving methicillin-resistant S. aureus (MRSA).1 Early use of vancomycin was associated with a number of adverse effects, including infusion-related toxicities, nephrotoxicity, and possible ototoxicity. Upon further investigation, it appears that the impurities in early formulations of vancomycin caused many of these adverse events.1–4 Its overall use was curtailed significantly with the development of semisynthetic penicillins (e.g., methicillin, oxacillin, nafcillin) that were considered less toxic.1–4 However, the steady rise in the number of MRSA infections since the early 1980s has once again brought vancomycin into the forefront as the primary treatment for infections caused by this organism....
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
Self-citationHundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Autoinduction and signal transduction in the regulation of staphylococcal virulence
Novick, R. P. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03526.x · Cited by 1,280 · cited 1×
“aureus that is responsible for orchestrating the expression of adherence factors, biofilm production, tolerance to vancomycin, and virulence factors.(66) The agr locus has been a subject of intense study because there appears to be a relationship between polymorphism in this gene cluster and patient response to vancom…”
BackgroundMartindale. The Extra Pharmacopoeia.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-687_2 · Cited by 1,111
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 4×
“Hidayat et al.(53) prospectively investigated the efficacy and toxicity of adjusting vancomycin troughs to achieve an unbound concentration of at least four times the MIC.”
BackgroundInfluentialLevine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836 · cited 2×
“Sakoulas et al.(52) reported a significant correlation between vancomycin susceptibilities and patient outcome.”
BackgroundSelf-citation
Research works printed but not linked: 5
- Virgincar, 2004, Glycopeptides (dalabavancin, oritavancin, teicoplanin, vancomycin), 181
- Cooper, 1986, The development of vancomycin, 1
- Geraci, 1977, Vancomycin, Mayo Clin Proc, 52, 631
- Boffi El Amari, 2004, High versus standard dose vancomycin for osteomyelitis, Scand J Infect Dis., 36, 712
- Dangerfield, 1960, Clinical use of vancomycin, Antimicrob Agents Chemother, 61, 428
Cited by
Items 901–1,000 of 1,002
Lei, X., Xiang, J., Yang, H., Bao, H., Zhu, Z. X., & Luo, H. (2023) · EFORT Open Reviews · doi:10.1530/eor-22-0130 · Cited by 12
Yu, Z., Liu, J., Yu, H., Zhou, L., Zhao, Y., Zhong, L., Jianping, Z., Liang, G., Yang, Y., Zheng, Y., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106812 · Cited by 12
Chen, Z., Taubert, M., Chen, C., Dokos, C., Fuhr, U., Weig, T. G., Zöller, M., Heck, S., Dimitriadis, K. A., Terpolilli, N. A., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00241-23 · Cited by 12
“Due to the occurrence of Gram-positive penicillin-resistant pathogens, vancomycin is a standard therapy for central nervous system (CNS) infections, specifically, nosocomial infections (3).”
BackgroundMethodMancino, F., Yates, P., Clark, B., & Jones, C. W. (2023) · World Journal of Orthopedics · doi:10.5312/wjo.v14.i8.589 · Cited by 12
Dose optimization and target attainment of vancomycin in children
Cafaro, A., Stella, M., Mesini, A., Castagnola, E., Cangemi, G., Mattioli, F., & Baiardi, G. (2024) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2024.110728 · Cited by 13
Yu, R., Dale, S. E., Yamamura, D. L. R., Stankus, V., & Lee, C. (2012) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2012/138470 · Cited by 12
Jobson, S., Moise, P. A., & Eskandarian, R. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.09.007 · Cited by 12
Incidence and Risk Factors for Vancomycin Nephrotoxicity in Acutely Ill Pediatric Patients
Woldu, H., & Guglielmo, B. J. (2017) · Journal of Pharmacy Technology · doi:10.1177/8755122517747088 · Cited by 12
Li, X., Wu, Y., Sun, S., Wang, Q., & Zhao, Z. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.11.005 · Cited by 13
Vancomycin-Associated Acute Kidney Injury with a Steep Rise in Serum Creatinine
Velez, J. C. Q., Obadan, N., Kaushal, A., Alzubaidi, M., Bhasin-Chhabra, B., Sachdev, S. H., Karakala, N., Arthur, J. M., Nesbit, R. M., & Phadke, G. M. (2018) · The Nephron journals/Nephron journals · doi:10.1159/000487149 · Cited by 12
Dorajoo, S. R., Winata, C. L., Goh, J. H. F., Ooi, S. T., Somani, J., Yeoh, L. Y., Lee, S. Y., Yap, C. W., Chan, A., & Chae, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00641 · Cited by 13
“However, there remains a lack of models specifically designed for dosing vancomycin in CKD (Moellering et al., 1981; Matzke et al., 1984; Rodvold et al., 1988; Rybak et al., 2009; Thomson et al., 2009; Cardile et al., 2015).”
BackgroundResultInfluentialVancomycin in ICU Patients with Gram-Positive Infections: Initial Trough Levels and Mortality
Alshehri, N., Ahmed, A. E., Yenugadhati, N., Javad, S., Sulaiman, K. A. A., Al‐Dorzi, H. M., Aljerasiy, M., & Badri, M. (2020) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s266295 · Cited by 12
“All of the patients received 15–20 mg/kg (as actual body weight) as an initial dose and some patients received a loading dose of vancomycin 25–30 mg/kg (based on actual body weight).(5) The outcomes of the study were 1) achieving therapeutic level in the initial trough level of vancomycin and 2) all cause 30day mortal…”
BackgroundMethodEffective synthesis of new benzo-fused macrocyclic and heteromacrocyclic bis(Schiff bases)
Ahmed, A. A. M., Mekky, A. E. M., & Sanad, S. M. H. (2021) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-021-02409-3 · Cited by 12
Hussain, K., Ikram, R., Gul, A., & Salat, M. S. (2021) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-021-00383-y · Cited by 12
“P & TC approved AKUH antibiotic guidelines are developed in accordance with the ASHP/IDSA guidelines [14] and drug monographs.”
BackgroundMethodKidd, J. M., Asempa, T. E., & Abdelraouf, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00013-1 · Cited by 12
Critical assessment of the revised guidelines for vancomycin therapeutic drug monitoring
Aljutayli, A., Thirion, D. J. G., & Nekka, F. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113777 · Cited by 12
Pai, M. P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.06.004 · Cited by 12
Ceftobiprole: The First Broad-Spectrum Anti–methicillin-resistant Staphylococcus aureus Beta-Lactam
Chahine, E. B., & Nornoo, A. O. (2010) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2010.12.007 · Cited by 12
Sulaiman, H., Abdul-Aziz, M. H., & Roberts, J. A. (2017) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0037-1602716 · Cited by 13
Data collection and research with MargheritaTre
Finazzi, S., Mandelli, G., Garbero, E., Mondini, M., Trussardi, G., Giardino, M., Tavola, M., & Bertolini, G. (2018) · Physiological Measurement · doi:10.1088/1361-6579/aad10f · Cited by 12
“The gray band denotes the optimal range of drug concentration (Rybak et al 2009).”
BackgroundReview of Antibiotic Dosing with Peritonitis in APD
Mancini, A., & Piraino, B. (2019) · Peritoneal Dialysis International · doi:10.3747/pdi.2018.00209 · Cited by 12
Gregory, E. R., Burgess, D. R., Cotner, S. E., VanHoose, J. D., Flannery, A. H., Gardner, B. M., Autry, E. B., Forster, D. W., Burgess, D. S., & Wallace, K. L. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019867494 · Cited by 12
“47 76%-100% 2 (8) 15 (27) 9 (19) 8 (23) 51%-75% 13 (52) 38 (68) 28 (60) 23 (68) 26%-50% 9 (36) 3 (5) 9 (19) 3 (9) 0%-25% 1 (4) 0 (0) 1 (2) 0 (0) Possible benefits of AUC monitoring justify any additional time required <.”
Li, H., Gao, L., Zhou, L., Wang, Y., Li, Q., Wang, J., Chen, T., Zhang, Y., Wang, T., & Shi, Q. (2019) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13338 · Cited by 12
Choi, S., Moon, S. M., Park, S., Lee, S. C., Jung, K. H., Sung, H., Kim, M., Jung, J., Kim, M. J., Kim, S., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01925-19 · Cited by 14
“Although these changes in the vancomycin MIC were small, decreases in the vancomycin AUC/MIC ratio would be sufficient to negatively affect treatment outcome, because an AUC/MIC ratio of 400 has been advocated as a target for the clinical effectiveness of vancomycin (20).”
BackgroundLines, J., Burchette, J. E., Kullab, S. M., & Lewis, P. O. (2020) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-020-01157-3 · Cited by 12
Haseeb, A., Alqurashi, M. K., Althaqafi, A. S., Alsharif, J. M., Faidah, H. S., Bushyah, M., Alotaibi, A. M. F., Elrggal, M. E., Mahrous, A. J., Abuhussain, S. S. A., et al. (2022) · Antibiotics · doi:10.3390/antibiotics11030409 · Cited by 12
Vancomycin Clearance in High-Volume Venovenous Hemofiltration
Paciullo, C. A., Harned, K. C., Davis, G. A., Connor, M. J., Jr., & Winstead, P. S. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1q488 · Cited by 12
Pharmacist‐led therapeutic drug monitoring: implementation of a successful credentialing model
Cairns, K. A., O'Brien, D. J., Corallo, C., Guidone, D., & Dooley, M. J. (2017) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1378 · Cited by 12
Prospective evaluation of vancomycin therapeutic usage and trough levels monitoring
Kabbara, W. K., Khoury, G. E., & Chamas, N. R. (2018) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.9800 · Cited by 12
Asti, L., Bartsch, S. M., Umscheid, C. A., Hamilton, K. T., Nachamkin, I., & Lee, B. Y. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.11.031 · Cited by 12
AUC-Based Monitoring of Vancomycin: Closing the Therapeutic Window
Biagi, M. J., Butler, D. A., & Wenzler, E. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.027391 · Cited by 12
Marvin, J. L., Levine, B. J., Papas, M. A., & Rosini, J. M. (2019) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2019.03.020 · Cited by 12
Chander, S., Kumari, R., Wang, H. Y., Mohammed, Y. N., Parkash, O., Lohana, S., Sorath, F., Lohana, A. C., Sadarat, F., & Shiwlani, S. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09927-4 · Cited by 15
“…the need for caution with this approach while treating mild noninvasive infections and infections caused by non-MRSA species responsive to vancomycin as the guidelines predominantly rely on pharmacological and toxicological data from patients treated for serious for severe MRSA infections [23].”
BackgroundGandia, P., Chaiben, S., Fabre, N., & Concordet, D. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13253 · Cited by 11
Fang, X., Gao, T., Luo, Z., & Pei, R. (2025) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2025.137681 · Cited by 11
Mbuku, R. B., Poilvache, H., Maigret, L., Vanbever, R., Bambeke, F. V., & Cornu, O. (2025) · Biofilm · doi:10.1016/j.bioflm.2025.100288 · Cited by 11
“Vancomycin is the reference treatment in clinical practice for severe MRSA infections [21,22].”
Lemaire, X., Valette, M., Dubreuil, L. J., Yazdanpanah, Y., Senneville, É., Loïez, C., Migаud, H., & Lemaire, X. (2010) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-010-0176-z · Cited by 11
“For vancomycin, considering EUCAST [19] and Clinical and Laboratory Standards Institute breakpoints [20], Staphylococcus aureus with MICs B 2 mg/l are considered susceptible strains.”
BackgroundEmerging drugs on methicillin-resistantStaphylococcus aureus
Liapikou, A., & Torres, A. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.813480 · Cited by 11
“Concurrent aminoglycosides and other known nephrotoxic agents (diuretics) are thought to increase the risk of nephrotoxicity during vancomycin therapy, in addition to medical conditions which include hemodynamic instability [29].”
BackgroundHaran, J. P., Goulding, M., Campion, M. G., Scully, G., Chandra, A., Goldberg, R., Day, A., McLendon, E., & Clark, M. A. (2020) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.12.012 · Cited by 11
Wang, H., Huang, L., Wang, J., Ni, Y., Zhu, Z., Gao, P., Hu, Y. W., Zhang, L., Yang, J., & Fang, L. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2473 · Cited by 11
“Recent study indicated that patients with vancomycin Cmin greater than 15 mg/L were at a greater risk of acute kidney injury,(23) so in our study, the steady-state Cmin (10 and 15 mg/L) were selected to determine the optimal initial dosing regimen.(7,11) Actual BW of individual simulated was 10, 20, 30, and 40 kg, and…”
MethodNew Vancomycin Dosing Guidelines for Hemodialysis Patients: Rationale, Caveats, and Limitations
Lewis, S. J., & Nolin, T. D. (2021) · Kidney360 · doi:10.34067/kid.0000192021 · Cited by 11
“5 approach was adapted from trough monitoring recommended in the 2009 guidelines (4).”
BackgroundMethodBang, J., Kang, H. I., Lee, H., Chong, Y. P., Hong, S., Lee, E., Choi, B., & Noh, G. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13597 · Cited by 11
Ahmed, A. A. M., Mekky, A. E. M., & Sanad, S. M. H. (2021) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4383 · Cited by 11
Experience of Vancomycin Therapeutic Drug Monitoring in Two Multidisciplinary Hospitals in Latvia
Mauliņa, I., Darbiniece, K., Miķelsone-Jansone, L., Erts, R., Bandere, D., & Krūmiņa, A. (2022) · Medicina · doi:10.3390/medicina58030370 · Cited by 13
“The guidelines outlined several important aspects, including serum concentration targets, analysis, and dosing to standardize vancomycin therapy [6].”
BackgroundInfluentialLing, J., Yang, X., Dong, L., Jiang, Y., Zou, S., & Hu, N. (2024) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2383 · Cited by 11
“Vancomycin, a bacteriostatic glycopeptide antibiotic, is the most frequently used antibiotic in critically ill patients for the treatment of Gram ‐ positive bacterial infections due to methicillin ‐ resistant Staphylococcus aureus strains (Rybak et al., 2009).”
BackgroundMaki, N., Ohkuchi, A., Tashiro, Y., Kim, M. R., Le, M., Sakamoto, T., Matsubara, S., & Hakamata, Y. (2012) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-012-1593-y · Cited by 11
“[13]; therefore, we hypothesized that the target VCM trough levels should be set between 10 and 20 mcg/mL.”
BackgroundMethodInfluentialMei, Q., Ye, Y., Zhu, Y., Cheng, J., Yang, H., Liu, Y., Li, H.-R., & Li, J. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.01.018 · Cited by 11
“50% [9], this arameter in rabbit tissue-cage fluid (TCF) is still unknown.”
BackgroundClinical use of the polymyxins: the tale of the fox and the cat
Wenzler, E., Bunnell, K. L., & Danziger, L. H. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.12.023 · Cited by 11
Tullu, M. S., Gogtay, N., Mali, N. B., Wandalkar, P. P., Deshpande, S. P., Ingale, V., & Thatte, U. M. (2019) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23275 · Cited by 11
“Pediatr Infect Dis J 1995;14(8):667–673.”
Synergistic Effects of Thiosemicarbazides with Clinical Drugs against S. aureus
Chudzik-Rząd, B., Malm, A., Trotsko, N., Wujec, M., Plech, T., & Paneth, A. (2020) · Molecules · doi:10.3390/molecules25102302 · Cited by 11
Teaford, H. R., Stevens, R. W., Rule, A. D., Mara, K. C., KASHANI, K. B., Lieske, J. C., O’Horo, J. C., & Barreto, E. F. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01487-20 · Cited by 11
“Guideline-recommended weight-based dose ranges were followed (25); however, adjusted body weight (0.”
BackgroundBhongsatiern, J., Stockmann, C. R., Tian, Y., Constance, J. E., Moorthy, G., Spigarelli, M. G., Desai, P. B., & Sherwin, C. M. T. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.650 · Cited by 11
Evaluation of Vancomycin Dosing and Monitoring in Adult Medicine Patients
Devabhakthuni, S., Gonzales, J. P., Tata, A. L., Lee, S. H. F., Shah, P., Offurum, A. I., & Gulati, M. S. (2012) · Hospital Pharmacy · doi:10.1310/hpj4706-451 · Cited by 11
“Based on previous studies and vancomycin guidelines, an appropriate trough concentration was defined as 10 to 20 mcg/mL.(4,6,15)”
BackgroundMethodInfluentialImaura, M., Kohata, Y., Kobayashi, K., Takahashi, H., Yokoyama, H., Akase, T., & Yamada, Y. (2011) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.131.563 · Cited by 11
Pile, J. C. (2011) · Journal of Hospital Medicine · doi:10.1002/jhm.854 · Cited by 11
Application of Antibiotic Pharmacodynamics and Dosing Principles in Patients With Sepsis
Droege, M. E., Fleet, S. L. V., & Mueller, E. W. (2016) · Critical Care Nurse · doi:10.4037/ccn2016881 · Cited by 16
“Although modern formulations are far less impure, the incidence of nephrotoxic effects is increased with concomitant administration of nephrotoxins such as aminoglycosides and amphotericin B.(64,67) Retrospective studies67-69 have revealed other risk factors for the nephrotoxic effects of vancomycin, including prolong…”
BackgroundViel‐Thériault, I., Martin, B., Thompson-Desormeaux, F., Blackburn, J., Moussa, A., & Autmizguine, J. (2019) · Journal of Perinatology · doi:10.1038/s41372-019-0519-2 · Cited by 11
Vancomycin volume of distribution estimation in adults with class III obesity
Dunn, R. D., Crass, R. L., Hong, J., Pai, M. P., & Krop, L. C. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz241 · Cited by 11
Krukas, A., Franklin, E. S., Bonk, C., Howe, J. L., Dixit, R. A., Adams, K., Krevat, S. A., Jones, R., & Ratwani, R. M. (2020) · Patient Safety · doi:10.33940/data/2020.3.3 · Cited by 11
Lorenzo, M. P., MacConaghy, L., Miller, C. D., Meola, G., Probst, L. A., Pratt, B., Steele, J., & Seabury, R. W. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017739324 · Cited by 10
“Current vancomycin dosing recommendations are intended for use in patients with methicillinresistant Staphylococcus aureus infection, and their applicability to the ED is uncertain.(17) To address any potential deviation in ED vancomycin dosing, the department of pharmacy has autonomy for vancomycin dosing at our inst…”
Backgroundde la Mària, C. G., Cañas, M.-A., Fernández-Pittol, M., Dahl, A., García‐González, J., Meneses, M. H., Cuervo, G., Moreno, A., Miró, J. M., & Marco, F. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2174969 · Cited by 11
Pan, K., Huang, Y., Xu, C., Zhangzhang, C., Ding, X., Xiaoyu, L., Xu, X., & Lv, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1260802 · Cited by 10
Gillett, E. M., Aleissa, M. M., Pearson, J. C., Solomon, D. A., Kubiak, D. W., Dionne, B., Edrees, H. H., Okenla, A., & Chan, B. T. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae600 · Cited by 10
“However, vancomycin therapeutic drug monitoring has traditionally consisted of trough-based monitoring to a goal of 15–20 mg/L as a surrogate for AUC estimations [4].”
MethodVancomycin Dosing Nomogram for Haemodialysis Patients
Jeremiah, C. J., Wills, C., Bayly, A., Perry, G. J., Davis, J. S., Tong, S. Y. C., & Currie, B. J. (2014) · Nephrology · doi:10.1111/nep.12270 · Cited by 10
Bounthavong, M., & Hsu, D. I. (2012) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.12.72 · Cited by 10
Peterson, M. B., Cohen, M. N., O’Neill, B. R., Garg, S., Child, J., Henthorn, T. K., & Galinkin, J. L. (2019) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004340 · Cited by 10
Ibrahim, M., Latif, A., Ammara, A., Ali, A., Ribeiro, A. I., Farooq, U., Ullah, F., Khan, A., Al‐Harrasi, A., Ahmad, M., et al. (2020) · Drug Development Research · doi:10.1002/ddr.21775 · Cited by 10
“…the clinically available macrocyclic antibiotics are azithromycin, erythromycin, vancomycin, daptomycin, bacitracin, spiramycin, and rifampin (Alvarez-Elcoro & Enzler, 1999; Chopra, 2007; Gulhane et al., 2014; Jones & Barry, 1987; Rybak et al., 2009; Zuckerman et al., 2011).”
Efficacy and Safety of Continuous Infusion of Vancomycin in Children: A Systematic Review
Moreno, M. A., Mejías-Trueba, M., Hidalgo, L. H., Goycochea-Valdivia, W. A., & Gil-Navarro, M. V. (2021) · Antibiotics · doi:10.3390/antibiotics10080912 · Cited by 10
“normal renal function when MIC is ≤1 mg/mL [7,8].”
BackgroundParra, D., Mesa, J. A. P., Cuervo, S. I., Díaz, J., Cortés, J. A., Silva, E. F., Saavedra, C., & Gómez-Rincón, J. C. (2022) · Antibiotics · doi:10.3390/antibiotics11111523 · Cited by 10
“In these guides, the recommendation of the objective was made AUC/MIC ≥ 400 as the main predictor of success with VAN therapy which contrasts with the previous version of this guide, where it was recommended to Cmin between 15− 20mg/L as the main objective [14].”
MethodChen, M., Lee, C., Gnyra, M., & Wong, M. (2022) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361221140368 · Cited by 10
Dose optimization of vancomycin in obese patients: A systematic review
Elrggal, M. E., Haseeb, A., Algethamy, M., Ahsan, U., Saleem, Z., Althaqafi, A. S., Alshuail, S. S., Alsiddiqi, Z. A., Iqbal, M. S., Alzahrani, A. F., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.965284 · Cited by 10
“Troughs should be at least 10 μg/mL, with targets of 15–20 μg/mL for microorganism with MIC ≥1 μg/ mL and for patients with serious infectious diseases (Rybak et al., 2009).”
BackgroundKim, H., & Jeong, T. (2023) · Annals of Laboratory Medicine · doi:10.3343/alm.2023.43.6.554 · Cited by 11
Vancomycin and Gentamicin Removal with the HA380 Cartridge during Experimental Hemoadsorption
Furukawa, T., Lankadeva, Y. R., Baldwin, I., Ow, C. P. C., Hood, S. G., May, C. N., & Bellomo, R. (2023) · Blood Purification · doi:10.1159/000534108 · Cited by 10
“However, 50 – 70% of vancomycin in plasma is protein bound [13], compared with less than 30% for gentamicin [11].”
BackgroundAnalysis of Vancomycin Therapeutic Drug Monitoring Trends at Pediatric Hospitals
Moffett, B. S., & Edwards, M. S. (2012) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31826fd98d · Cited by 10
“Variability in vancomycin utilization and monitoring was compared across healthcare institutions, age groups and in relation to publication of the adult consensus guidelines for serum vancomycin concentration monitoring.(1) Outcomes (eg, length of stay, mortality) for pediatric hospitals in the lowest quartile for fre…”
BackgroundMethodInfluentialMcDaneld, P. M., Spooner, L. M., Mohr, J., & Belliveau, P. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013508272 · Cited by 12
“The IDSA vancomycin dosing consensus suggests considering alternatives to vancomycin in patients whose S aureus isolate has a vancomycin MIC ≥2 μg/mL.(19) One treatment option in these circumstances may be daptomycin, a lipopeptide antibiotic that is FDA approved for treatment of S aureus bacteremia, right-sided infec…”
BackgroundInfluentialVancomycin MIC as a predictor of outcome in MRSA bacteraemia in the UK context
Hope, R., Blackburn, R. M., Verlander, N. Q., Johnson, A. P., Kearns, A., Hill, R., Hopkins, S., Sheridan, E. A. S., Livermore, D. M., Scarborough, M., et al. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt234 · Cited by 10
Therapeutic monitoring of vancomycin
Alves, M. L. P., de Melo, G. A. N., Yamada, S. S., & Nishiyama, P. (2012) · Acta Scientiarum Health Sciences · doi:10.4025/actascihealthsci.v34i2.10617 · Cited by 10
A new approach to Vancomycin utilization evaluation: A cross-sectional study in intensive care unit
Farsaei, S., Mahmoodian, A., & Abbasi, S. (2016) · Journal of Research in Pharmacy Practice · doi:10.4103/2279-042x.192453 · Cited by 10
Levin, D. A., Glasheen, J. J., & Kiser, T. H. (2016) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2016.710073 · Cited by 10
“Vancomycin Nomogram Design The nomogram was designed using current recommendations to dose vancomycin at 15 – 20 mg/kg every 8–12 hours in patients with normal renal function (Table 1) [1].”
InfluentialLu, C., Guo, Y., Wang, S., Wang, Z., Chen, L., Lv, J., Qi, X., Chen, Z., Han, L., Zhang, X., et al. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01714 · Cited by 10
Faine, B. A., Mohr, N. M., Dietrich, J. N., Meadow, L., Harland, K. K., & Chrischilles, E. A. (2017) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2017.5.33901 · Cited by 10
Narayanan, N., Adams, C., Kubiak, D. W., Cheng, S., Stoianovici, R. N., Kagan, L., & Brunetti, L. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s196264 · Cited by 10
Sauter, M., Uhl, P., Foerster, K. I., Mohr, I., Höne, R. T., Merle, U., Burhenne, J., & Haefeli, W. E. (2019) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2019.06.015 · Cited by 10
Yavuz, S. Ş., Akar, A., Aydoğdu, S., Berzeg-Deniz, D., Demir, H., Hazırolan, T., Özatık, M. A., Özer, N., Sarğın, M., Topçuoğlu, N., et al. (2020) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2020.01954 · Cited by 13
Team Approach: Pediatric Musculoskeletal Infection
Dhar, A. V., Huang, C. J., Sue, P. K., Patel, K., Farrow-Gillespie, A. C., Hammer, M. R., Zia, A. N., Mittal, V. S., & Copley, L. A. (2020) · JBJS Reviews · doi:10.2106/jbjs.rvw.19.00121 · Cited by 10
Protocole d'immunisation du Québec
sociaux, Q. M. D. L. S. E. D. S. (2009) · Cited by 10
Hou, Y., Ren, J., Li, J., Jin, X., Gao, Y., Li, R., Zhang, J., Wang, X., Li, X., & Wang, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.690157 · Cited by 12
“However, it is difficult to precisely determine multiple serum/tissue vancomycin concentrations during the same dosing interval to calculate the AUC in clinical practice (Rybak et al., 2009).”
BackgroundMethodInfluentialKim, S., Lee, H., Hwang, N. Y., Kim, K., Park, H., & Lee, S. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s285488 · Cited by 10
Kim, Y. K., Lee, J. H., Jang, H. J., Zang, D. Y., & Lee, D. H. (2022) · Antibiotics · doi:10.3390/antibiotics11060743 · Cited by 10
“Because serial sampling may not be easy in a real clinical setting, the trough concentration was recommended as a practical surrogate marker for the AUC [18].”
MethodCao, G., Liang, X., Zhang, J., Zhou, Y., Wu, J., Zhang, Y., Chen, Y., Huang, J., Liu, X., & Yu, J. (2015) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12323 · Cited by 10
“A vancomycin-specific treatment guideline published in 2009 recommends vancomycin trough concentration of 10–15 mg/L for general infections and 15–20 mg/L for serious infections.(3,4) To date, many clinicians in China still use a trough concentration of 5–10 mg/L because there is no very strong evidence to claim the s…”
BackgroundRhinocerebral Mucormycosis Complicated by Bacterial Brain Abscess
Cano, P., Horseman, M. A., & Surani, S. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181f0aad1 · Cited by 10
Bianco, C., Arena, F., Rossetti, B., Tordini, G., Migliorini, L., Galluzzi, P., Cerase, A., Luca, A. D., Rossolini, G. M., & Montagnani, F. (2014) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2014.04.004 · Cited by 11
Niveau de preuve pour le suivi thérapeutique pharmacologique de la vancomycine
Jelassi, M. L., Benlmouden, A., Lefeuvre, S., Mainardi, J., & Billaud, E. M. (2011) · Therapies · doi:10.2515/therapie/2011005 · Cited by 10
Performance of a Divided-Load Intravenous Vancomycin Dosing Strategy for Critically Ill Patients
Denetclaw, T. H., Dowling, T. C., & Steinke, D. T. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013510395 · Cited by 10
“Organisms intermediately sensitive and resistant to vancomycin are increasingly prevalent and are associated with poor treatment outcomes.(1,4) This has resulted in updated recommendations for attaining trough concentrations of at least 15 to 20 μg/mL in complicated infections while maintaining all vancomycin trough c…”
BackgroundPhillips, C. J., Wisdom, A. J., Eaton, V. S., Woodman, R. J., & McKinnon, R. A. (2016) · SpringerPlus · doi:10.1186/s40064-016-1966-2 · Cited by 10
Antimicrobial Agent Dosing in Infants
Johnson, J. K., & Laughon, M. M. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.06.017 · Cited by 18
“Vancomycin is usually administered intermittently (although continuous dosing has been used [discussed later]) and the target trough concentrations are 15 to 20 mg/mL, although these targets are derived from adult data.(64) Guidelines from the Infectious Diseases Society of America recommend similar trough targets in…”
BackgroundWei, W., Qin, X., Cheng, D.-H., Lu, H., & Liu, T. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12437 · Cited by 10
“Vancomycin is a bactericidal glycopeptide antibiotic widely used in children for treating serious Gram-positive infections, particularly methicillin-resistant Staphylococcus aureus (MRSA) infections.(1) In our institution, approximately 46 8% of S.”
BackgroundMethodImplementation of a prioritized scoring tool to improve time to pharmacist intervention
Harvin, A., Mellett, J., Knoell, D. L., Mirtallo, J. M., Naseman, R. W., Brown, N. V., & Tubbs, C. R. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150787 · Cited by 10
Zamoner, W., Pierri, I. G., Eid, K. Z. C., de Almeida, L. M. B., dos Santos, A., Balbi, A. L., & Ponce, D. (2020) · Infection and Drug Resistance · doi:10.2147/idr.s219989 · Cited by 10
“It was identified that this value is reached when trough serum concentrations of vancomycin (when the medicine is at a lower concentration) is 15–20 mg/L for major infections.(10,11) However, there have been few studies to evaluate monitoring of its serum concentration and association with clinical outcomes, requiring…”
BackgroundInfluentialIs Vancomycin Ototoxicity a Significant Risk?
Shields, R. K., Martello, J. L., & Potoski, B. A. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00537-09 · Cited by 10
“aureus and/or for increasing therapeutic efficacy through pharmacodynamic target achievement of an area under the concentration-time curve or MIC of 400 (1, 7).”
Background
Metadata
- Authors
- Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Albany Medical Center Hospital (US)
- University of Minnesota (US)
- Beth Israel Deaconess Medical Center (US)
- University of Wisconsin–Madison (US)
- New Orleans, LA
- Ochsner Health System (US)
- Division of General Internal Medicine, WSU
- Corresponding author
- Rybak, Michael
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-01-01
- Volume
- 66
- Issue
- 1
- Pages
- 82-98
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2133120422
- Semantic Scholar
- f97f86b0eb5acbf0d7b5f8d4197a9e67f28c94ab
- Cited by
- 1,795
- References
- 130
- Citations by year
- 2026: 41 · 2025: 63 · 2024: 60 · 2023: 72 · 2022: 94 · 2021: 110 · 2020: 135 · 2019: 129 · 2018: 123 · 2017: 113 · 2016: 104 · 2015: 120 · 2014: 122 · 2013: 119 · 2012: 120
- FWCI
- 61.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, therapeutic drug monitoring, glycopeptides, methicillin-resistant Staphylococcus aureus, MRSA infection, Gram-positive bacterial infections, nephrotoxicity, ototoxicity, infusion-related toxicity, adverse drug reactions, pharmacokinetics, pharmacodynamics
- MeSH terms
- Adult, Anti-Bacterial Agents, Humans, Vancomycin, Drug Monitoring, Gram-Positive Bacterial Infections, Practice Guidelines as Topic, Vancomycin Resistance, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.